Cargando…
Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/ https://www.ncbi.nlm.nih.gov/pubmed/32369265 http://dx.doi.org/10.1002/ehf2.12716 |
_version_ | 1783561593482641408 |
---|---|
author | Dieterle, Thomas Schaefer, Stefan Meyer, Ina Ackermann, Gabriele Ahmed, Kashan Hullin, Roger |
author_facet | Dieterle, Thomas Schaefer, Stefan Meyer, Ina Ackermann, Gabriele Ahmed, Kashan Hullin, Roger |
author_sort | Dieterle, Thomas |
collection | PubMed |
description | AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, and hospital‐based care, while patients with chronic heart failure (CHF) are frequently followed‐up in primary care. The THESEUS study aimed to characterize the transition to sac/val and early maintenance period of HFrEF in primary care. METHOD AND RESULTS: THESEUS was a prospective, observational, non‐interventional study, performed at primary care sites throughout Switzerland. Patient characteristics, sac/val transition, and maintenance were reported at study enrolment and approximately 3 and 6 months after sac/val initiation. The primary endpoint was achievement of 200 mg BID sac/val with maintenance for ≥12 weeks. Secondary outcomes included dosing regimens, healthcare utilization in the 6 months prior to sac/val initiation and during the study, patient well‐being, safety, and tolerability. Fifty‐eight patients with CHF were enrolled from 45 primary care centres. Six patients were excluded, and 19 achieved the primary endpoint (36.5%, Achievers). Non‐Achievers underwent fewer titration steps than Achievers (1.9 ± 0.9 vs. 3.1 ± 1.4). In both groups, patient well‐being improved and the percentage of New York Heart Association III patients decreased. Healthcare utilization decreased (19% vs. 30.8% in the 6 months pre‐enrolment period). The most frequent reasons for target dose non‐achievement were asymptomatic and symptomatic hypotension (15.3% and 12.1%, respectively). CONCLUSIONS: Results from THESEUS suggest that transition to sac/val is manageable in primary care, with a safety profile corresponding to reports from specialized heart failure care. |
format | Online Article Text |
id | pubmed-7373939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73739392020-07-22 Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) Dieterle, Thomas Schaefer, Stefan Meyer, Ina Ackermann, Gabriele Ahmed, Kashan Hullin, Roger ESC Heart Fail Original Research Articles AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, and hospital‐based care, while patients with chronic heart failure (CHF) are frequently followed‐up in primary care. The THESEUS study aimed to characterize the transition to sac/val and early maintenance period of HFrEF in primary care. METHOD AND RESULTS: THESEUS was a prospective, observational, non‐interventional study, performed at primary care sites throughout Switzerland. Patient characteristics, sac/val transition, and maintenance were reported at study enrolment and approximately 3 and 6 months after sac/val initiation. The primary endpoint was achievement of 200 mg BID sac/val with maintenance for ≥12 weeks. Secondary outcomes included dosing regimens, healthcare utilization in the 6 months prior to sac/val initiation and during the study, patient well‐being, safety, and tolerability. Fifty‐eight patients with CHF were enrolled from 45 primary care centres. Six patients were excluded, and 19 achieved the primary endpoint (36.5%, Achievers). Non‐Achievers underwent fewer titration steps than Achievers (1.9 ± 0.9 vs. 3.1 ± 1.4). In both groups, patient well‐being improved and the percentage of New York Heart Association III patients decreased. Healthcare utilization decreased (19% vs. 30.8% in the 6 months pre‐enrolment period). The most frequent reasons for target dose non‐achievement were asymptomatic and symptomatic hypotension (15.3% and 12.1%, respectively). CONCLUSIONS: Results from THESEUS suggest that transition to sac/val is manageable in primary care, with a safety profile corresponding to reports from specialized heart failure care. John Wiley and Sons Inc. 2020-05-05 /pmc/articles/PMC7373939/ /pubmed/32369265 http://dx.doi.org/10.1002/ehf2.12716 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Articles Dieterle, Thomas Schaefer, Stefan Meyer, Ina Ackermann, Gabriele Ahmed, Kashan Hullin, Roger Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title | Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title_full | Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title_fullStr | Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title_full_unstemmed | Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title_short | Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) |
title_sort | introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (theseus) |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/ https://www.ncbi.nlm.nih.gov/pubmed/32369265 http://dx.doi.org/10.1002/ehf2.12716 |
work_keys_str_mv | AT dieterlethomas introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus AT schaeferstefan introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus AT meyerina introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus AT ackermanngabriele introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus AT ahmedkashan introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus AT hullinroger introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus |